@unicornbiotech@a_a_free 100%. Comes down to $REGN perception of monthly probability of success. $REGN stands to lose up to $2b+ in cumulative FCF if interrupted by monthly. $KNSA could be worth $5b+ with monthly- avoiding $REGN payments. Or $REGN could cut their losses and take $KNSA out for $4b today
@unicornbiotech@a_a_free Listen to today’s conference call. $KNSA is developing KPL-387, monthly dosed Arcalyst, which $REGN has no economic rights. They were open today about the concept of switching patients to KPL-387 from Arcalyst upon approval. $REGN annuity is going away if $KNSA KPL-387 works
@Akston_Capital@kingdomcapadv I did the math the other day on $MAGN and think annual EBITDA needs to drop below $225m before they can’t cover debt payments and maintenance capex. Revenue challenged but $225m EBITDA requires a severe drop which seems unlikely given the company’s generally stable end markets
@chasericker3 And now it’s commonplace. What is the argument for btc reserve companies trading at a premium to the underlying value of their btc holdings?
@ToffCap Macro concerns (discretionary spending, cost/freight inflation) combined with debt burden have weighed on $FLWS stock. But the business historically has generated significant cash flow in a strong economy.
@ToffCap The McCann family controls $FLWS through the Class B shares which vote 10-1. Saw odd insider buying in 2023 (Pres Hartnett & CFO Shea bought for the first time in their 30 yr tenures) coinciding with C McCann's resignation for health reasons and J McCann's reinstatement
Director White purchased $190,000 of $EOLS. Stock’s valuation does not reconcile with management’s 2028 expectations. Will be posting full thoughts on the opportunity in $EOLS and its share gain story from $ABBV and $IPSEY
Perhaps most notably, CEO James has only been a seller of stock in recent years, despite purchasing $500,000 in $DOMO stock at $6.50 in April.
James Prior Trades:
-James sold $5M of stock in 2022 at prices ranging from $13-50
-James sold $1M of stock between 2023-2024 at $10
Notably, this comes at a pivotal time for $DOMO as the business is adjusting its pricing to a consumption model (70% of its current ARR now under the consumption model with a goal of 90% by year end) and updating its go to market strategy using strategic partners $SNOW